Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Treasury Shares: 2017-2024

Historic Treasury Shares for Autolus Therapeutics (AUTL) over the last 7 years, with Dec 2024 value amounting to $32,412.

  • Autolus Therapeutics' Treasury Shares rose 160.81% to $94,375 in Q3 2025 from the same period last year, while for Sep 2025 it was $94,375, marking a year-over-year increase of 160.81%. This contributed to the annual value of $32,412 for FY2024, which is 72.16% down from last year.
  • Per Autolus Therapeutics' latest filing, its Treasury Shares stood at $32,412 for FY2024, which was down 72.16% from $116,436 recorded in FY2023.
  • In the past 5 years, Autolus Therapeutics' Treasury Shares ranged from a high of $505.4 billion in FY2020 and a low of $1,500 during FY2021.
  • Its 2-year average for Treasury Shares is $74,424, with a median of $74,424 in 2023.
  • Data for Autolus Therapeutics' Treasury Shares shows a maximum YoY tumbled of 100.00% (in 2021) over the last 5 years.
  • Yearly analysis of 4 years shows Autolus Therapeutics' Treasury Shares stood at $505.4 billion in 2020, then crashed by 100.00% to $1,500 in 2021, then reached $116,436 in 2023, then tumbled by 72.16% to $32,412 in 2024.